NKARTA INC. - COMMON

Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs

07 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

01 Oct 2021 08:08:00 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conference

14 Sep 2021 08:32:00 By Nasdaq GlobeNewswire

Nkarta Reports Second Quarter 2021 Financial Results and Business Progress

12 Aug 2021 16:02:00 By Nasdaq GlobeNewswire

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

14 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Nkarta to Present at Upcoming Investor Conference

16 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

14 Jun 2021 07:01:00 By Nasdaq GlobeNewswire

Nkarta Announces June 2021 Investor Conference Schedule

25 May 2021 07:30:00 By Nasdaq GlobeNewswire

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

13 May 2021 16:02:00 By Nasdaq GlobeNewswire

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

28 Apr 2021 08:02:00 By Nasdaq GlobeNewswire

Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

25 Mar 2021 16:03:00 By Nasdaq GlobeNewswire

Nkarta Announces February and March 2021 Investor Conference Schedule

17 Feb 2021 16:03:00 By Nasdaq GlobeNewswire